Back to journals
Academic Journal

Biological Psychiatry

37 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 37 psychedelic papers Blossom tracks from Biological Psychiatry line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Biological Psychiatry carry?

Sourced

Tracked papers by publication year; 5 earlier papers published before 2011. Click a year for the running total.

8papers published in 2024

+33% vs 2023

36 published by 2024

Browse papers→

Don't read as the journal's total output: only the 37 of 37 tracked psychedelic papers from Biological Psychiatry with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Biological Psychiatry publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
18
Neuroimaging & Brain Measures
16
Anxiety Disorders
6
Schizophrenia
5
Microdosing
5
Addiction & Substance Use
4
Safety & Risk Management
4
Creativity
3
Other
15

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Biological Psychiatry cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
11
LSD
10
Ketamine
9
MDMA
4
DMT
1
Salvia Divinorum
1
Nitrous Oxide
1
2C-X
1
Other
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Biological Psychiatry has 37 tracked papers indexed in Blossom (1996–2025) from 217 authors, most often covering Psilocybin, LSD and Ketamine, across Healthy Volunteers, Depressive Disorders and Neuroimaging & Brain Measures.

Published Papers

Open Accessindividual

Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats

This cross-species experimental study (n=21 humans; n=10 rats) finds that psilocin (18.2mg/70kg for humans; 0.3mg/kg for rats) impairs the ability to distinguish between static and moving images in both humans and rats. In humans, the impairment aligns with psilocin plasma levels and self-reported hallucination intensity. In rats, the effect is specific to motion perception, providing the first evidence of psilocin-induced visual distortions across species.

Published
Journal
Biological Psychiatry
Authors
Vejmola, C., Šíchová, K., Syrová, K., Janečková, L., Koudelka, V., Tesař, M., Nikolič, M., Viktorin, V., Viktorinová, M., Tylš, F., Korčák, J., Kelemen, E., Nekovářová, T., Brunovský, M., Horáček, J., Kuchař, M., Páleníček, T.
Paywallindividual

Psilocybin and 4-Bromo-2,5-Dimethoxyphenethylamine (2C-B) at Encoding Distort Episodic Familiarity

This re-analysis of an RCT study (n=20) tested the acute effects of psilocybin and 2C-B on the encoding of emotional episodic memories. The study finds that both psychedelics impair estimates of recollection and familiarity, increase familiarity-based false alarms for emotional stimuli, and affect metamemory, indicating a common neurocognitive mechanism across these drugs.

Published
Journal
Biological Psychiatry
Authors
Doss, M. K., Mallaroni, P., Mason, N. L., Ramaekers, J. G.
Open Accessindividual

Neural Mechanisms of Resting-State Networks and the Amygdala underlying the Cognitive and Emotional Effects of Psilocybin

This follow-up fMRI analysis of an RCT of healthy subjects (n=24) finds that psilocybin (15mg/70kg) led to a pattern of decreased top-down effectivity between the default mode network (DMN), salience network (SN), and central executive network (CEN) to the amygdala.

Published
Journal
Biological Psychiatry
Authors
Stoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., Razi, A.
Open Accessindividual

Experiences of Awe Mediate Ketamine's Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression

This randomised controlled trial (n=116) investigated the psychological mechanisms of ketamine's antidepressant effects. Participants receiving ketamine reported significantly heightened feelings of awe compared to those receiving a placebo. Awe experiences, as measured by the Awe Experience Scale (AWE-S), mediated depression outcomes (% improvement in MADRS scores) at multiple time points (24 hours and 5, 12, 21, and 30 days) post-infusion, indicating a potential role of awe in ketamine's therapeutic efficacy for depression.

Published
Journal
Biological Psychiatry
Authors
Aepfelbacher, J., Panny, B., Price, R.
Open Accessindividual

Comparing neural correlates of consciousness: from psychedelics to hypnosis and meditation

This comparative neuroimaging study (n=107) compares the neural correlates of two pharmacological methods, psilocybin (n=23) and LSD (n=25), and two non-pharmacological methods, hypnosis (n=30) and meditation (n=29), in inducing altered states of consciousness (ASC). The results reveal distinct connectivity patterns associated with pharmacological and non-pharmacological interventions, predictability at an individual level, and unique behavioural-neural relationships between psilocybin and LSD, all contributing to a broader understanding of the mechanisms of ASC and their potential therapeutic applications in psychiatric disorders.

Published
Journal
Biological Psychiatry
Authors
Rieser, N. M.
Open Accessindividual

Effective-connectivity of thalamocortical interactions following d-amphetamine, LSD, and MDMA administration

This re-analysis of a double-blind, placebo-controlled, crossover study (n=25) investigated the effects of LSD, MDMA and dextroamphetamine on brain measures (thalamocortical and corticothalamic interactions in resting-state fMRI data). Compared to placebo, all three substances increased the effective-connectivity from the thalamus to specific unimodal cortices while reducing their influence on the thalamus, revealing increased bottom-up and decreased top-down information flow; LSD uniquely increased effective-connectivity to both unimodal and transmodal cortices.

Published
Journal
Biological Psychiatry
Authors
Avram, M., Müller, F., Preller, K. H., Razi, A., Rogg, H., Korda, A., Holze, F., Vizeli, P., Ley, L., Liechti, M. E., Borgwardt, S.

Quick Facts

Papers Indexed
37
h-Index
367
Open Access
No
Publisher
Elsevier
Country
United States
Website
Visit